Results 111 to 120 of about 31,788 (164)

[Corrigendum] Inactivation of von Hippel‑Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR‑210/VMP1 signaling pathway. [PDF]

Int J Mol Med
Liu T, Zhao L, Chen W, Li Z, Hou H, Ding L, Li X.   +6 more
europepmc   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer. [PDF]

Mol Oncol
Abad L, Tosatto SCE, Leonardi E.
europepmc   +1 more source

Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancer. [PDF]

Front Oncol
Donninger H, Ferrill R, Hobbing K, Vos M, Clark GJ.   +4 more
europepmc   +1 more source

Clinical outcomes of HIF-2α inhibition in Von Hippel-Lindau disease: a multicenter real-world study. [PDF]

Oncologist
Al Abbas M, Zarka J, Silva AC, Cingolani F, Sarfraz MU, Jang A, Khan MA, Nahhat F, Tan W, Costello BA, Abdul-Muhsin H, Bin Riaz I, Zakharia Y.   +12 more
europepmc   +1 more source

Bridging E3 Ligase Binding and Targeted Degradation Through Fluorescence Polarization. [PDF]

Int J Mol Sci
González-Pico L, Camino T, Ortigueira S, Prieto-Díaz R, Sotelo E, Majellaro M.   +5 more
europepmc   +1 more source

Genetic Heterogeneity in Renal Cell Carcinoma: A Case of Concurrent Clear Cell and Papillary Renal Carcinomas. [PDF]

Case Rep Urol
Kerckhofs A, Dautricourt S, van Kempen L, De Wachter S, Ramadhan A.   +4 more
europepmc   +1 more source

<i>VHL</i> gene fragment analysis: large inversion detection in <i>Alu</i> region for clinical applications. [PDF]

J Med Genet
Baugher RN, Mellott SD, Pike KM, Young TB, Lawhorn HE, Hewitt SM.   +5 more
europepmc   +1 more source

Recent advances in the development of tag-targeted protein degradation systems. [PDF]

J Enzyme Inhib Med Chem
Li B, Lu Y, Che J, Dong X.
europepmc   +1 more source

Diabetic ketoacidosis associated with pancreatic involvement in a patient with von Hippel-Lindau syndrome: a case report. [PDF]

Front Endocrinol (Lausanne)
Zhang Y, Liu F, Cao X, Guo D, Zhu Y, Sun H.   +5 more
europepmc   +1 more source